Novonesis A/S

NSIS B

DK0060336014

Specialty Chemicals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-07-16 EDT			5-day change	1st Jan Change
425.6 ^DKK	-0.86%		-2.27%	+14.69%

06-18	Transcript : Novozymes A/S - Analyst/Investor Day
06-18	European shares advance ahead of inflation data, more c.bank speakers	RE

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen

January 26, 2024 at 06:07 am

Please read the full announcement in PDF

Attachment

2024_01_All_Regulatory_Approvals_Obtained

Latest news about Novonesis A/S

Transcript : Novozymes A/S - Analyst/Investor Day	06-18
European shares advance ahead of inflation data, more c.bank speakers	06-18	RE
NOVONESIS : Key segments outperform in average Q1 24 showing	05-10
Transcript : Novozymes A/S, Q1 2024 Sales/ Trading Statement Call, May 03, 2024	05-03
Novonesis Provides Sales Guidance for the Year 2024	05-03	CI
Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023	04-30	CI
Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023	04-08	CI
China to speed up 'new productive forces', vice president says	03-26	RE
Nordic Shares Rose Thursday; Embracer Group Series B Topped Leaders	03-21	DJ
Transcript : Novozymes A/S, 2024 Guidance/Update Call, Mar 21, 2024	03-21
Novonensis expects 2024 adjusted EBITDA margin of 35%	03-21	RE
Novonesis Provides Earnings Guidance for the Year 2024	03-21	CI
Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development	03-18	MT
Biotalys and Novonesis Announces Manufacturing and Commercialization Partnership for EVOCA NG	03-18	CI
FMC Partners With Novonesis in Canada for Biosolution Products	03-12	MT
Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West	03-07	CI
Novozymes A/S Announces Board Appointments	03-04	CI
Transcript : Novozymes A/S - Shareholder/Analyst Call	03-04
Novo Nordisk's controlling shareholder plans to invest about $35 billion by 2030	02-12	RE
Novozymes A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
NOVOZYMES : Q4 23: destocking noise offsets recovery in other key segments	02-08
Novozymes, Chr. Hansen Complete Merger Settlement	02-02	MT
Transcript : Novozymes A/S, 2023 Earnings Call, Feb 01, 2024	02-01
Novozymes Completes Merger with Chr. Hansen After Securing Final Registration, Issuing B Shares	01-29	MT
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S.	01-28	CI

Novonesis A/S (formerly Novozymes A/S) is the world's leading producer of enzymes and microorganisms for industrial companies. Net sales break down by market as follows: - industry of cleaning and household maintenance products (28.5%); - bioenergy (24.8%); - food industry and human health (22.1%); - technical and cereal industries (12.8%): microorganisms used in the field of wastewater treatment, technical enzymes intended for the textile, leather, pulp and paper industries; - agriculture and animal feed industry (11.8%): enzymes used to improve the productivity and digestion of certain foods. Net sales are geographically distributed as follows: Denmark (1.3%), Europe/Middle East/Africa (33.5%), North America (33.9%), Asia/Pacific (18.5%) and Latin America (12.8%).

Sector

Specialty Chemicals

Calendar

2024-08-27 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVONESIS : Key segments outperform in average Q1 24 showing

May 10, 2024 at 12:32 pm

More Strategies

Ratings for Novonesis A/S

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

429.3 DKK

Average target price

455.6 DKK

Spread / Average Target

+6.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Industrial Biotechnology Chemicals

	1st Jan change	Capi.
NOVONESIS A/S	+14.69%	29.17B
CATHAY BIOTECH INC.	-25.23%	3.41B
BORREGAARD ASA	+10.85%	1.76B
PUYANG HUICHENG ELECTRONIC MATERIAL CO., LTD.	-22.23%	554M
HENAN JINDAN LACTIC ACID TECHNOLOGY CO.,LTD.	-32.95%	361M
BIO-ON S.P.A.	-81.65%	216M
CHEMCON SPECIALITY CHEMICALS LIMITED	-10.04%	116M

Industrial Biotechnology Chemicals

Novonesis A/S

Equities

NSIS B

DK0060336014

Specialty Chemicals

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen

Latest news about Novonesis A/S

Chart Novonesis A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novonesis A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Industrial Biotechnology Chemicals